Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients

Table 2

Patients treated with favipiravir.

Treated with favipiravir	Within three days of admission (n = 75)	More than three days after admission (n = 28)
Ages, mean (SEM)	57.8 (1.8)	59.2 (3.4)
Survival/death (n) (%)	75/0 (100%–0%)	27/1 (96.4%–3.6%)
Non-ICU (n) (%)	63 (84%)	19 (67.9%)
ICU (n) (%)	12 (16%)	9 (32.1%)
Comorbidities/no comorbidities (n) (%)	47/28 (62.7%–37.3%)	19/9 (67.9%–32.1%)
Days in hospital (SEM)	8.8 (0.6)	13.4 (1.6)